Bioprocessing of Recombinant CHO-K1, CHO-DG44, and CHO-S: CHO Expression Hosts Favor Either mAb Production or Biomass Synthesis

Cho 8_8

As no standard chemotherapy regimen has been established for advanced gastric cancer, this study sought to evaluate the efficacy and safety of combination chemotherapy that included paclitaxel and leucovorin (LV)-modulated infusional 5-fluorouracil (5-FU) in metastatic gastric cancer. Patients received a three-hour infusion of 175 mg/m2 of paclitaxel on day 1. A bolus of 20 mg/m2 of LV was then...

OPTIMISATION OF CHO CELL GROWTH AND RECOMBINANT INTERFERON-y PRODUCTION

The optimisation of recombinant protein production by animal cell cultures is important for the economic feasibility of these processes. Simultaneously with product yield, product authenticity is a crucial aspect to consider as it may per se affect the therapeutic value of such proteins. More defmed culture media are being developed, particularly to ensure batch product consistency. A Chinese H...

Metabolite profiling of CHO cells: Molecular reflections of bioprocessing effectiveness.

Whilst development of medium and feeds has provided major advances in recombinant protein production in CHO cells, the fundamental understanding is limited. We have applied metabolite profiling with established robust (GC-MS) analytics to define the molecular loci by which two yield-enhancing feeds improve recombinant antibody yields from a model GS-CHO cell line. With data across core metaboli...

Won - Seob Cho 2005

Intraclonal Protein Expression Heterogeneity in Recombinant CHO Cells

Therapeutic glycoproteins have played a major role in the commercial success of biotechnology in the post-genomic era. But isolating recombinant mammalian cell lines for large-scale production remains costly and time-consuming, due to substantial variation and unpredictable stability of expression amongst transfected cells, requiring extensive clone screening to identify suitable high producers...